RxDoctor Payments Data

James Kline, MD

Obstetrics & Gynecology · Saint Joseph, MONPI 1558320531

Payments from drug & device makers

$888in general payments, 2019–2025

Across 63 payments — averaging $14.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Indivior Inc.$397
  • Novo Nordisk$194
  • Orexo US, Inc.$160
  • Philips North America LLC$44
  • Lilly USA, LLC$42
  • Braeburn Inc.$38
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$888100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$888 in reported general payments places this provider in the 60th percentile of 750 obstetrics & gynecology providers in Missouri.

See all obstetrics & gynecology providers in Missouri

Medicare billing

Part B allowed, 2024
$16,520
Medicare patients
19
Services billed
199

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SuboxoneBuprenorphine Hcl/Naloxone Hcl129$73,495
SublocadeBuprenorphine20$44,095
MounjaroTirzepatide20$21,228
OzempicSemaglutide17$16,261
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl109$9,984
Buprenorphine Hcl38$4,231
Clonazepam71$874
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen24$800
Lorazepam25$390
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen13$293
Chlordiazepoxide Hcl11$193
Levothyroxine Sodium27$121
Alprazolam18$73
Zolpidem Tartrate25$62

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Indivior Inc.Suboxone, Sublocade$397$117,590149 claims
Lilly USA, LLCMounjaro$42$21,22820 claims
Novo NordiskOzempic$194$16,26117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 750 obstetrics & gynecology providers in Missouri.

Other obstetrics & gynecology in Saint Joseph

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →